1. What Is the Addiction Treatment Market?
The Addiction Treatment Market covers the pharmacological treatments for the substance use disorders including the opioid use disorder, the alcohol use disorder, and the tobacco use disorder. The emerging treatments target the stimulant use disorder and the cannabis use disorder. These affect hundreds of millions of people globally. The agonist maintenance treatments, the antagonist blockade therapies, and the aversion treatments provide the pharmacological management of the withdrawal, the craving, and the relapse prevention that the chronic brain disease model of addiction requires. Addiction pharmacotherapy uses the full opioid agonist methadone and the partial agonist buprenorphine including the buprenorphine-naloxone formulation for the opioid use disorder maintenance. The naltrexone opioid antagonist treats the abstinence-based OUD and AUD, and the acamprosate and disulfiram treat the alcohol use disorder. The nicotine replacement therapy, varenicline, and bupropion treat the tobacco cessation. The addiction treatment market is advancing with the long-acting injectable buprenorphine subdermal implant and the monthly subcutaneous depot. These address the medication diversion and the adherence challenges of the daily sublingual buprenorphine by providing the sustained drug level. The depot formulation eliminates the daily dosing opportunity for the diversion and the dose manipulation.
2. Addiction Treatment Market Size & Forecast
3. Emerging Technologies
- Monthly extended-release buprenorphine Sublocade subcutaneous injection achieves the stable buprenorphine plasma level that eliminates the peak and trough of the sublingual formulation. The depot formulation removes the daily dosing decision that the sublingual medication requires from the treatment adherence equation. The OUD patient who cannot maintain the daily medication routine benefits from the extended-release formulation that passively ensures the treatment compliance.
- Naltrexone Vivitrol monthly intramuscular injection for the OUD and AUD demonstrated superior abstinence rates in the XBOT trial that compared the extended-release naltrexone with the buprenorphine-naloxone for the OUD patient who completed the detoxification. The antagonist treatment serves the abstinence-motivated patient. The patient who cannot or will not take the opioid agonist treatment selects the antagonist.
- Varenicline Chantix mechanism of action as the partial nicotinic alpha4beta2 receptor agonist reduces the nicotine withdrawal and the craving while blocking the nicotine reward that the full receptor agonism from smoking provides. The drug achieves the 28 percent 6-month continuous abstinence that the EAGLES trial confirmed. The FDA label update resolved the cardiovascular safety concern by the 2021 removal of the boxed warning.
- Ketamine and MDMA addiction treatment research from the ketamine plus therapy for the alcohol use disorder trial demonstrated superior 6-month abstinence rates. The MDMA-assisted psychotherapy for the PTSD frequently co-occurs with the substance use disorder. The psychedelic-assisted approach is what the addiction treatment is cautiously exploring beyond the psychedelic therapy's primary indication.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Alcohol USe Disorder Market.
4. Key Market Opportunity
A significant commercial opportunity in the Addiction Treatment market is driven by long-acting injectable buprenorphine and naltrexone expansion, where the improved adherence and reduced diversion potential of LAI formulations drive prescribing growth in opioid use disorder treatment. Companies with approved LAI OUD therapy capture this adherence-driven opportunity. A parallel growth driver is centered on formal evaluation of GLP-1 agonists for substance use disorders. As LAI OUD adoption grows and GLP-1 trials progress, the addressable opportunity is expanding from oral OUD pharmacotherapy toward LAI and potential GLP-1-based addiction treatment.
5. Top Companies in the Addiction Treatment Market
The following organisations hold leading positions in the Addiction Treatment Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Indivior
- Alkermes
- Pfizer
- Camurus
- Braeburn
- Titan Pharmaceuticals
- Sun Pharma
- Orexo
- Teva Pharmaceutical
- Mallinckrodt
6. Market Segmentation
The Addiction Treatment Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Substance | OpioidAlcoholNicotineStimulantCannabis |
| By Mechanism | Agonist MaintenanceAntagonistAversionCraving Reduction |
| By Setting | OutpatientSpecialty Addiction Clinic |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Addiction Treatment Market trajectory over the forecast period:
Monthly Sublocade Subcutaneous Buprenorphine Depot Eliminating Daily Dosing and Achieving Stable Plasma Level Without Peak-Trough Has Removed the Diversion and Adherence Challenges of Sublingual Buprenorphine That Require Daily Supervised Dosing in High-Risk Adherence Settings.Indivior's Sublocade demonstrated 90-plus percent weeks with no illicit opioid use at 24 weeks in ATLAS versus approximately 60% for control, and the subcutaneous monthly injection eliminates the daily tablet administration that creates diversion risk for sublingual buprenorphine films that are the dominant current OUD treatment modality. Monthly injection buprenorphine produces plasma levels that remain continuously in the therapeutic range without the missed-dose gaps that create craving and relapse risk from daily sublingual therapy, particularly important in the early weeks of OUD treatment where medication-taking consistency is most challenging. Camurus's CAM2038 buprenorphine depot injection weekly formulation provides an additional adherence-improvement option, and both products are recommended in SAMHSA guidelines as preferred formulations for patients with documented adherence challenges or risk of diversion.
Extended-Release Naltrexone Vivitrol Monthly IM Injection Demonstrating Superior Abstinence in XBOT vs Buprenorphine-Naloxone Has Provided the Antagonist Treatment That the Abstinence-Motivated OUD Patient Who Refuses Opioid Agonist Therapy Accepts as the Non-Agonist Alternative.Alkermes's Vivitrol demonstrated 36.1-day abstinence advantage over placebo in VIVITROL trial in criminal justice-referred patients who completed supervised detoxification, and real-world prescribing data from drug courts and correctional settings show Vivitrol as the most commonly used medication-assisted treatment in criminal-justice diversion programmes where supervised injection eliminates the daily adherence and diversion concerns of sublingual buprenorphine. The full opioid receptor blockade of naltrexone completely eliminates opioid reinforcement in motivated patients, making Vivitrol appropriate for patients committed to opioid abstinence who find buprenorphine's partial agonism psychologically unsatisfying as a maintenance strategy. The opioid detoxification requirement before Vivitrol initiation is the principal practical barrier that limits Vivitrol use compared with buprenorphine-based medications that can be initiated without prior detoxification in patients currently using opioids.
UCL Ketamine Plus Therapy Superior 6-Month AUD Abstinence and MDMA-Assisted PTSD-Comorbid Addiction Treatment Research Are Establishing the Psychedelic-Assisted Psychotherapy as an Emerging Addiction Treatment Approach Beyond Pharmacological Agonist and Antagonist Therapies.Preclinical data from multiple animal models showing semaglutide and liraglutide reduce alcohol preference, nicotine self-administration, and opioid conditioned-place preference has generated substantial clinical interest in testing GLP-1 agonists for addictive behaviour reduction in human populations. Novo Nordisk's retrospective analysis of semaglutide users in clinical databases shows reduced rates of alcohol use disorder diagnoses and alcohol-related hospitalisation, and phase 2 clinical trials at Yale and Johns Hopkins are prospectively testing semaglutide in alcohol use disorder patients. The proposed mechanism involves GLP-1 receptor activation in nucleus accumbens and ventral tegmental area reward circuits that reduces the neurobiological salience of substance-associated cues, providing a direct pharmacological suppression of craving that complements but does not replace the receptor-specific approaches used by naltrexone and buprenorphine.
For related market intelligence, see the Opioid Addiction Market.
8. Segmental Analysis
By substance, the opioid use disorder segment dominated the Addiction Treatment Market in 2025, as Indivior's buprenorphine formulations and Alkermes's Vivitrol anchored medication-assisted treatment across the largest addiction population, generating the largest share of addiction pharmacotherapy revenue.
By mechanism, the long-acting injectable segment is projected to register the highest growth rate through 2034, as extended-release buprenorphine from Indivior and Camurus improves adherence and reduces diversion, shifting treatment from daily oral dosing toward monthly depot administration across addiction care.
9. Regional Analysis
Regional demand patterns across the Addiction Treatment Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Addiction Treatment Market in 2025, accounting for approximately 44% of global revenue, due to US prescribing volume for buprenorphine and the large opioid use disorder treatment population following X-waiver elimination expanding prescriber access. Moreover, LAI buprenorphine and naltrexone adoption are most advanced in the US. In addition, the opioid crisis has driven substantial addiction treatment investment. Regional dominance is attributed to this combination of patient population and access expansion.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Addiction Treatment Market through 2034, driven by expanding opioid use disorder treatment programmes and methadone and buprenorphine access across European healthcare systems. The region is also witnessing LAI buprenorphine adoption growing. Moreover, alcohol use disorder pharmacotherapy is established. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Addiction Treatment Market was valued at USD 10.86 Bn in 2025 and is projected to reach USD 22.62 Bn by 2034, growing at a CAGR of 8.5% over the 2026–2034 forecast period.
The Addiction Treatment Market is projected to grow at a CAGR of 8.5% from 2026 to 2034.
North America dominated the Addiction Treatment Market in 2025, accounting for approximately 44% of global revenue, due to US prescribing volume for buprenorphine and the large opioid use disorder treatment population following X-waiver elimination expanding prescriber access.
The leading companies in the Addiction Treatment Market include Indivior, Alkermes, Pfizer, Camurus, Braeburn, Titan Pharmaceuticals, Sun Pharma, Orexo, Teva Pharmaceutical, Mallinckrodt.
Monthly sublocade subcutaneous buprenorphine depot eliminating daily dosing and achieving stable plasma level without peak-trough has removed the diversion and adherence challenges of sublingual buprenorphine that require daily supervised dosing in high-risk adherence settings.
By substance, the opioid use disorder segment dominated the Addiction Treatment Market in 2025, as Indivior's buprenorphine formulations and Alkermes's Vivitrol anchored medication-assisted treatment across the largest addiction population, generating the largest share of addiction pharmacotherapy revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.